Evidence map›Paper›PMID 32755847›Full record

SynthesisDiabetes & metabolic syndrome

Impact of COVID -19 in cancer patients on severity of disease and fatal outcomes: A systematic review and meta-analysis.

Abhijeet Ashok Salunke, Kunal Nandy, Subodh Kumar Pathak, Jaymin Shah, Mayur Kamani, Viswanth Kottakota, Praveen Thivari, Apurva Pandey, Keval Patel, Priyank Rathod and 3 more

Abstract readComparative StudyMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Diabetes & metabolic syndrome. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 10 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 10 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Abhijeet Ashok SalunkeDepartment of Surgical Oncology, Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India. Electronic address: drabhijeetsalunke@gmail.com.
Kunal NandyDepartment of Surgical Oncology, Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India.
Subodh Kumar PathakDepartment of Orthopedics, MMIMSR, M M Deemed to be University, Mullana, Ambala, India.
Jaymin ShahDepartment of Orthopedic Oncology, Osteocare Ortho Onco Clinic, Ahmedabad, Gujarat, India.
Mayur KamaniDepartment of Surgical Oncology, Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India.
Viswanth KottakotaDepartment of Surgical Oncology, Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India.
Praveen ThivariDepartment of Orthopedics, MMIMSR, M M Deemed to be University, Mullana, Ambala, India.
Apurva PandeyDepartment of Radiation Oncology, MMIMSR, MM Deemed to be University, Ambala, Haryana, India.
Keval PatelDepartment of Surgical Oncology, Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India.
Priyank RathodDepartment of Surgical Oncology, Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India.
Supreet BhattDepartment of Surgical Oncology, Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India.
Pariseema DaveDepartment of Surgical Oncology, Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India.
Shashank PandyaDepartment of Surgical Oncology, Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and aimsbackgroundCurrently there is limited knowledge on cancer and COVID-19; we conducted a systematic review and meta-analysis to evaluate the impact of cancer on serious events including ICU admission rate and mortality in COVID 19.

methodsPubMed, Cochrane Central Register of Clinical Trials were searched on April 16, 2020, to extract published articles that reported the outcomes of cancer in COVID-19 patients. The search terms were "coronavirus" and "clinical characteristics" with no language or time restrictions. We identified 512 published results and 13 studies were included in the analysis.

resultsThere were 3775 patients, of whom 63 (1·66%) had a cancer. The pooled estimates of ICU admission in COVID 19 patients with and without cancer were 40% versus 8·42%.The odds ratio of ICU admission rates between the cancer and non-cancer groups was 2.88 with a 95% CI of 1·18 to 7·01 (p = 0·026). The pooled estimates of death rate in COVID -19 patients with and without cancer were 20·83% versus 7·82%. The odds ratio of death rates between the cancer and non-cancer groups was 2.25 with a 95% CI ranging from 0·71 to 7·10 with p value of 0·166. The pooled prevalence of cancer patients was 2% (95 CI 1-4).

conclusionsPresence of cancer in COVID-19 leads to higher risk of developing serious events i.e. ICU admission, mechanical ventilation and mortality. The presence of cancer has a significant impact on mortality rate in COVID-19 patients.

Indexed as

BetacoronavirusComorbidityCoronavirus InfectionsCOVID-19Critical CareHumansNeoplasmsPandemicsPneumonia, ViralPrevalenceSARS-CoV-2CancerCorona diseaseCOVID-19ICU StayMortality rateNon cancerOncology

Identifiers

PMID32755847
PMCPMC7833306

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.